NATPARA (PARATHYROID HORMONE): payments to doctors
Payments that named NATPARA (PARATHYROID HORMONE) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $735K
- Providers
- 2,670
- Transactions
- 5,784
- Average per transaction
- $127
The per-transaction average — $127 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,670 providers the average total is $275, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Shire North American Group Inc | $618,011 | 84.1% |
| Takeda Pharmaceuticals U.S.A., Inc. | $117,037 | 15.9% |